Exact Sciences recently announced 2017 second quarter earnings results, which exceeded our expectations. Revenue reached $57.6 million, up 19% sequentially, and completed Cologuard test volume totaled 135,000, up 35% sequentially.
Cologuard® revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests
- Revenue guidance raised to $230-240 million for 2017, from $195-205 million
- Guidance for Cologuard tests to be completed during 2017 increased to at least 550,000 tests, from at least 470,000
- 11,000 additional providers ordered Cologuard for the first time during the second quarter, and insurance coverage expanded to 86 percent of target population
MADISON, Wis., July 25, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $57.6 million and completed approximately 135,000 Cologuard tests during the quarter ended June 30, 2017. Second-quarter 2017 revenue and completed Cologuard test volume grew 172 percent and 149 percent from the same period of 2016, respectively.
Golfer launches multi-year, Cologuard®-branded campaign
MADISON, Wis., June 22, 2017 /PRNewswire/ -- Exact Sciences today announced it is teaming up with Madison professional golfer Jerry Kelly to help drive home the importance of colorectal cancer screening. Beginning at this week's American Family Insurance Championship, Kelly will wear a Cologuard-branded hat for the next two years at tournaments around the country to help raise awareness of colon cancer and the importance of regular screening beginning at age 50 for individuals at average risk.
AdvaMed (Advanced Medical Technology Association) gave Cologuard high marks as a case study showcasing the value of diagnostic tests in the U.S. healthcare system in a report they published last month.
Colorectal cancer kills approximately 50,000 Americans per year – more than breast cancer (41,000/year) and prostate cancer (26,000/year).
Exact Sciences recently announced our first quarter 2017 financial results, highlighting the accelerating growth trajectory for Cologuard. Beyond the headline-making news, we continue to see a large market opportunity for Cologuard. While changing the standard of care will take time and investment in our infrastructure, we have never been more confident in the long-term growth of Cologuard and Exact Sciences.
Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests
- Gross margin expands to 65 percent during first quarter
- Revenue guidance raised to $195-205 million for 2017, from $170-180 million;
- Guidance for completed Cologuard tests increased to at least 470,000 tests, from at least 415,000;
- 10,000 additional providers ordered Cologuard during the first quarter, and insurance coverage expanded to 78 percent.
MADISON, Wis., April 27, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $48.4 million and completed approximately 100,000 Cologuard tests during the quarter ended March 31, 2017. First-quarter 2017 revenues and completed Cologuard test volume grew 226 percent and 150 percent from the same period of 2016, respectively.
Topics: Investor Relations
MADISON, Wis., April 4, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) included Cologuard® in its updated Medicare Advantage Star Ratings program. Medicare Advantage plans now can help increase their Star Ratings when their beneficiaries complete Cologuard, Exact Sciences' non-invasive colon cancer screening test.
AACR abstract highlights methylation markers capable of detecting all types of lung cancer with more than 90% sensitivity and specificity
MADISON, Wis., March 1, 2017 /PRNewswire/ -- A study from Exact Sciences Corp. (Nasdaq: EXAS) and Mayo Clinic released today by the American Association of Cancer Research (AACR) shows promise for the development of a blood-based lung cancer test. Researchers conducted a multi-round study of nearly 400 patients, which demonstrated high accuracy for detecting lung cancer at all stages.
Exact Sciences’ first mission is to help eradicate colon cancer. That mission is on the minds of our team members every single day, and March gives us an opportunity to be even louder about the work we do. Right now, our team members are preparing to take part in some big events to help spread awareness about the nation’s second deadliest cancer and the need for screening.